Keywords: ImmunoGen, Amgen, IMGN901, Cancer, Resarch, Milestone

ImmunoGen enters second licensing deal with Amgen, worth up to $34 million; presents strong data on IMGN901

Article | 20 November 2009

Print This

ImmunoGen has licensed the exclusive right to use its maytansinoid Targeted Antibody Payload (TAP) technology to US biotechnology major Amgen ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in